Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1609-1618

  Loupakis, Fotios ^a   Cremolini, Chiara ^a   Masi, Gianluca ^a   Lonardi, Sara ^a   Zagonel, Vittorina ^b   Salvatore, Lisa ^b   Cortesi, Enrico ^c   Tomasello, Gianluca ^e   Ronzoni, Monica ^f   Spadi, Rosella ^g   Zaniboni, Alberto ^h   Tonini, Giuseppe ^d   Buonadonna, Angela ⁱ   Amoroso, Domenico ^j   Chiara, Silvana ^k   Carlomagno, Chiara ^l   Boni, Corrado ^m   Allegrini, Giacomo ⁿ   Boni, Luca ^o   Falcone, Alfredo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e CREMONA HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^h Fondazione Poliambulanza   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j Ospedale Versilia   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^m S MARIA NUOVA HOSPITAL   (Italy)

ⁿ Ospedale Felice Lotti   (Italy)

^o CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VENOUS THROMBOEMBOLISM; VOMITING; ARTICLE; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84908139591     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1403108     Document Type: Conference Paper

References (16)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
2. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
3. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
4. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516.
5. Hedrick E, Kozloff M, Hainsworth J. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006; 24: 3536. abstract.
6. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-14.
7. Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004; 15: 1766-72.
8. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-6.
9. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-52.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, 2006 (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf).
12. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-17.
13. Koopman M, Simkens L, May A, Mol L, van Tinteren H, Punt CJA. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32: Suppl 3: LBA388. abstract.
14. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50.
15. National Comprehensive Cancer Network. Colon Cancer (Version 3.2014), 2014 (http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf).
16. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as firstline treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-75.